JP2007505033A5 - - Google Patents

Download PDF

Info

Publication number
JP2007505033A5
JP2007505033A5 JP2006519734A JP2006519734A JP2007505033A5 JP 2007505033 A5 JP2007505033 A5 JP 2007505033A5 JP 2006519734 A JP2006519734 A JP 2006519734A JP 2006519734 A JP2006519734 A JP 2006519734A JP 2007505033 A5 JP2007505033 A5 JP 2007505033A5
Authority
JP
Japan
Prior art keywords
seq
composition
amino acid
acid sequence
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006519734A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007505033A (ja
Filing date
Publication date
Priority claimed from US10/888,805 external-priority patent/US7368537B2/en
Application filed filed Critical
Publication of JP2007505033A publication Critical patent/JP2007505033A/ja
Publication of JP2007505033A5 publication Critical patent/JP2007505033A5/ja
Pending legal-status Critical Current

Links

JP2006519734A 2003-07-15 2004-07-14 呼吸器合胞体得ウイルス感染に対するサブユニットワクチン Pending JP2007505033A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48780403P 2003-07-15 2003-07-15
US56758604P 2004-05-03 2004-05-03
US10/888,805 US7368537B2 (en) 2003-07-15 2004-07-09 Subunit vaccine against respiratory syncytial virus infection
PCT/CA2004/001007 WO2005007189A1 (en) 2003-07-15 2004-07-14 Subunit vaccine against respiratory syncytial virus infection

Publications (2)

Publication Number Publication Date
JP2007505033A JP2007505033A (ja) 2007-03-08
JP2007505033A5 true JP2007505033A5 (enExample) 2007-08-30

Family

ID=34084525

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006519734A Pending JP2007505033A (ja) 2003-07-15 2004-07-14 呼吸器合胞体得ウイルス感染に対するサブユニットワクチン

Country Status (9)

Country Link
US (2) US7368537B2 (enExample)
EP (2) EP1651264B1 (enExample)
JP (1) JP2007505033A (enExample)
AT (1) ATE451119T1 (enExample)
AU (1) AU2004257363A1 (enExample)
CA (1) CA2532164A1 (enExample)
DE (1) DE602004024542D1 (enExample)
ES (1) ES2337901T3 (enExample)
WO (1) WO2005007189A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1372706B1 (en) * 2001-03-09 2010-12-01 ID Biomedical Corporation of Quebec Proteosome-liposaccharide vaccine adjuvant
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
JP4966661B2 (ja) * 2003-10-22 2012-07-04 アイディー バイオメディカル コーポレイション オブ ケベック 生得的免疫およびアレルギー性免疫を活性化させるための組成物および方法
NZ578727A (en) * 2004-06-25 2011-03-31 Brigham & Womens Hospital Proteosome compositions and methods for treating neurological disorders
US8563002B2 (en) 2007-12-24 2013-10-22 Glaxosmithkline Biologicals, S.A. Recombinant RSV antigens
KR20110045008A (ko) * 2008-07-18 2011-05-03 아이디 바이오메디컬 코포레이션 오브 퀘벡 키메라 호흡기 세포융합 바이러스 폴리펩티드 항원
WO2010075491A2 (en) * 2008-12-24 2010-07-01 University Of Rochester Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins
US9566323B2 (en) * 2009-06-19 2017-02-14 Eyegene Inc. Vaccine for cervical cancer
SG176807A1 (en) 2009-06-24 2012-01-30 Id Biomedical Corp Quebec Vaccine
PL2445526T3 (pl) 2009-06-24 2017-08-31 Glaxosmithkline Biologicals S.A. Rekombinowane antygeny rsv
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
MX2012000372A (es) 2009-07-06 2012-02-28 Variation Biotechnologies Inc Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas.
EP4183412B1 (en) 2009-07-15 2024-08-14 GlaxoSmithKline Biologicals SA Rsv f protein compositions and methods for making same
US8846056B2 (en) * 2009-08-04 2014-09-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control Anti-RSV immunogens and methods of immunization
CN102695523A (zh) 2009-09-10 2012-09-26 诺华有限公司 针对呼吸道疾病的组合疫苗
US8730396B2 (en) * 2010-06-23 2014-05-20 MindTree Limited Capturing events of interest by spatio-temporal video analysis
US10487332B2 (en) 2010-07-06 2019-11-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
FI4005592T3 (fi) * 2010-07-06 2023-01-13 Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille
CN103153284B (zh) 2010-07-06 2015-11-25 诺华股份有限公司 含有其pKa值有利于RNA递送的脂质的脂质体
PT3243526T (pt) 2010-07-06 2020-03-04 Glaxosmithkline Biologicals Sa Distribuição de arn para despoletar múltiplas vias imunitárias
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
CN106008716B (zh) 2010-07-07 2019-08-13 人工细胞科技公司 呼吸道合胞病毒抗原组合物和方法
RS63890B1 (sr) * 2010-08-31 2023-02-28 Glaxosmithkline Biologicals Sa Mali lipozomi za isporuku rnk koja kodira imunogen
JP5911870B2 (ja) * 2010-08-31 2016-04-27 ノバルティス アーゲー 免疫原をコードするｒｎａの送達のためのｐｅｇ化リポソーム
KR102266691B1 (ko) 2010-10-11 2021-06-23 노파르티스 아게 항원 전달 플랫폼
KR20120068647A (ko) * 2010-12-18 2012-06-27 아이진 주식회사 개선된 면역반응을 유도하는 백신
AU2012205315B2 (en) * 2011-01-13 2017-05-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US10736844B2 (en) 2011-01-13 2020-08-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
RU2456020C1 (ru) * 2011-03-30 2012-07-20 Государственное образовательное учреждение дополнительного профессионального образования Российская медицинская академия последипломного образования Федерального агентства по здравоохранению и социальному развитию (ГОУ ДПО РМАПО Росздрава) Способ профилактики гриппа и острых респираторных инфекций у детей с бронхиальной астмой
JP2014518620A (ja) * 2011-04-26 2014-08-07 モレキュラー エクスプレス，インコーポレイテッド リポソーム製剤
RS56748B1 (sr) 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Pre-fuzioni rsv f antigeni
JP2014522842A (ja) 2011-07-06 2014-09-08 ノバルティス アーゲー 免疫原性組み合わせ組成物およびその使用
CA2894442C (en) 2012-01-12 2020-01-21 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP4008354A1 (en) 2012-01-27 2022-06-08 Variation Biotechnologies Inc. Methods and compositions for therapeutic agents
SI2879702T1 (sl) 2012-08-01 2020-02-28 Bavarian Nordic A/S Cepivo na osnovi rekombinantnega modificiranega virusa vakcinacije Ankara (MVA) proti respiratornemu sincitialnemu virusu (RSV)
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
SG11201500573RA (en) 2012-08-06 2015-02-27 Glaxosmithkline Biolog Sa Method for eliciting in infants an immune response against rsv and b. pertussis
SG11201600709TA (en) 2013-08-05 2016-02-26 Glaxosmithkline Biolog Sa Combination immunogenic compositions
US9415101B2 (en) * 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
KR101695518B1 (ko) * 2014-09-30 2017-01-12 이화여자대학교 산학협력단 호흡기 신시치아 바이러스 범용 백신
CA3004924A1 (en) 2015-11-10 2017-05-18 Ohio State Innovation Foundation Methods and compositions related to accelerated humoral affinity
EP3694548A4 (en) * 2017-10-13 2021-10-20 Trellis Bioscience, LLC CONFORMATIONAL EPITOPES IN THE CENTRAL PRESERVED REGION OF THE G PROTEIN OF RESPIRATORY SYNCYTIAL VIRUS
WO2020033742A1 (en) 2018-08-08 2020-02-13 Trellis Bioscience, Llc Improved rsv passive and active vaccines

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US5726292A (en) * 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
PT854729E (pt) * 1995-09-18 2004-08-31 Us Army Med Res Mat Com Usamrm Metodos melhorados para a producao de vacinas de subunidade multivalentes de proteossomas complexados nao covalentemente
US5848152A (en) 1995-09-26 1998-12-08 Motorola, Inc. Communication device having interchangeable faceplates and active keypad cover
CA2302833C (en) 1997-09-19 2007-05-08 American Cyanamid Company Peptides derived from the attachment (g) protein of respiratory syncytial virus
US6699478B1 (en) * 1997-09-19 2004-03-02 Wyeth Holdings Corporation Enhanced immune response to attachment (G) protein of Respiratory Syncytial Virus
JP3980884B2 (ja) 2000-02-15 2007-09-26 アイディー バイオメディカル コーポレイション オブ ケベック プロテオソーム・インフルエンザ・ワクチン
FR2819810B1 (fr) 2001-01-23 2004-05-28 Pf Medicament Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
EP1372706B1 (en) * 2001-03-09 2010-12-01 ID Biomedical Corporation of Quebec Proteosome-liposaccharide vaccine adjuvant
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection

Similar Documents

Publication Publication Date Title
Aguilar et al. Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen
Manocha et al. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target
Tamura et al. Enhancement of protective antibody responses by cholera toxin B subunit inoculated intranasally with influenza vaccine
JP2012501959A5 (enExample)
JP2007505033A (ja) 呼吸器合胞体得ウイルス感染に対するサブユニットワクチン
JP7403733B2 (ja) インフルエンザｈａスプリットワクチンの製造方法
JP2011506433A5 (enExample)
WO1999014334A1 (en) Peptides derived from the attachment (g) protein of respiratory syncytial virus
KR100341958B1 (ko) 백신조성물
WO2019045090A1 (ja) インフルエンザｈａスプリットワクチンの製造方法
AU2022262841A9 (en) Compositions and methods for preventing rsv and piv3 infections
CN101891825B (zh) 乙肝核心蛋白与结核抗原或抗原片段的重组融合蛋白及用途
US7527798B2 (en) Composition and method for preventing or treating a virus infection
US7354589B2 (en) Multiple antigenic agents and methods for using the same
Park et al. Effect of epitope-CpG-DNA-liposome complex without carriers on vaccination of respiratory syncytial virus infection
US7740860B2 (en) Composition and method for preventing or treating a virus infection
Nguyen et al. Subunit vaccine candidates engineered from the central conserved region of the RSV G protein aimed for parenteral or mucosal delivery
Horvath et al. Diego Cantoni 3, Reinhold Horlacher 4, Armin Günther 4, Alexander Brosig 4, Jenny Morath 4, Barbara Jakobs 4, Marcus Groettrup, Heinz Hoschuetzky 5, Jacques Rohayem 6 & Jan ter Meulen 7Ε
de Haan et al. Evaluation of a liposome-supplemented intranasal influenza subunit vaccine in a murine model system: induction of systemic and local mucosal immunity
CA2168885C (en) Vaccine compositions
李秀玲 et al. Development of RSV Vaccines
Niederman Prevention of community-acquired pneumonia
MX2008005634A (en) Prime boost vaccine for the protection of equines against equine influenza